Published in Eksp Klin Farmakol on January 01, 2011
Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) (2006) 0.84
[Virulence of Mycobacteria tuberculosis]. Probl Tuberk (2002) 0.83
Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro. Antiviral Res (2003) 0.77
[Pulmonary tuberculosis caused by Mycobacterium tuberculosis of different genotypes]. Probl Tuberk Bolezn Legk (2003) 0.77
[Combined therapy of pulmonary tuberculosis by using recombinant interleukins]. Probl Tuberk Bolezn Legk (2003) 0.77
[Effectiveness of new diagnostic drug Diaskintest in children for tuberculosis diagnostic]. Probl Tuberk Bolezn Legk (2009) 0.76
[Antioxidant and membranoprotector treatment of chronic pyelonephritis]. Eksp Klin Farmakol (2011) 0.76
[INFLUENCE OF ANGIOPROTECTOR DRUGS ON THE EFFICACY OF CYTOSTATIC THERAPY (EXPERIMENTAL STUDY)]. Eksp Klin Farmakol (2016) 0.75
[Cycloferon efficacy in the treatment of acute respiratory tract viral infection and influenza during the morbidity outbreak in 2009-2010]. Antibiot Khimioter (2010) 0.75
[Protective effect of cycloferon in experimental influenza]. Vopr Virusol (2001) 0.75
Pathways of apoptosis regulation in hepatocytes induced by first-line antitubercular drugs. Bull Exp Biol Med (2015) 0.75
[The therapeutic efficacy of cycloferon and the pharmacological activity of interferon inducers]. Ter Arkh (2014) 0.75
[Experimental study of cytoprotector effect of succinate-containing drugs on functional activity of liver]. Eksp Klin Farmakol (2010) 0.75
[Problem of osteopoikilosis]. Klin Med (Mosk) (1993) 0.75
[Pathogenetic therapy of tuberculosis of respiratory organs during sanatorium-and-spa treatment]. Vopr Kurortol Fizioter Lech Fiz Kult (2009) 0.75
[Comparative efficacy of clinical use of reamberin, remaxol and ademethionine in patients with tuberculosis of the respiratory organs and liver drug-injury]. Antibiot Khimioter (2013) 0.75
[Diagnosis and treatment of urinary bladder dysfunctions in patients with nephrotuberculosis]. Urologiia (2007) 0.75
[Pharmacological activity of runihol and S-adenosyl-L-methionine in rats with experimental liver damage by reserve antituberculosis drugs]. Eksp Klin Farmakol (2013) 0.75
[Activating effect of bestim on the macrophages in experimental tuberculosis of varying severity]. Probl Tuberk Bolezn Legk (2003) 0.75
[Effect of cycloferon on the evolution of cervical and vaginal cancer in mice]. Vopr Onkol (2000) 0.75
[Course of sarcoidosis in childhood, adolescence and young adulthood]. Pediatriia (1982) 0.75
[Lymph node tuberculosis of the ductus arteriosus in children]. Probl Tuberk (1981) 0.75
[The hepatoprotective activity of remaxol and S-adenosyl-L-methionine for liver damage caused by reserve-series antituberculosis drugs]. Arkh Patol (2013) 0.75
[Correction of postischemic reperfusion injury complications by cytoflavin]. Biull Eksp Biol Med (2000) 0.75
[Design and study of new agents having antitubercular activity: the original compound perchlosone as a potent agent of etiotropic therapy for tuberculosis]. Probl Tuberk (1999) 0.75
Neuroprotective effect of cytoflavin during compression injury of the spinal cord. Bull Exp Biol Med (2005) 0.75
[Anti-tuberculous activity of amikacin]. Probl Tuberk (1986) 0.75
[The hepatotropic activity of runihol and ademethionine against experimental liver damage caused by first-line antituberculosis drugs]. Arkh Patol (2014) 0.75
[Preclinical and clinical trials of the new tuberculosis drug perchlozon]. Ter Arkh (2016) 0.75
[Efficacy of cytoflavin in the treatment of chronic cerebral ischemia]. Klin Med (Mosk) (2010) 0.75
[Immunotropic and antihypoxant therapy of experimental drug-sensitive and drug-resistant tuberculosis]. Patol Fiziol Eksp Ter (2013) 0.75
[The effectiveness of influenza vectors expressing the protective mycobacterial antigen ESAT-6 in the complex therapy of generalized tuberculosis in mice]. Probl Tuberk Bolezn Legk (2008) 0.75
[Effect of hepatoprotector remaxol infusion on liver function in obstructive jaundice model in rats]. Eksp Klin Farmakol (2010) 0.75
[Detoxicating properties of remaxol with respect to multiple organ failure during severe ethanol poisoning]. Eksp Klin Farmakol (2010) 0.75
[Postgraduate training of pharmacists at the Kiev Institute of Physician Postgraduate Training]. Farm Zh (1973) 0.75
[Effect of infusion hepatoprotectors on hepatic function in experimental cholestasis]. Khirurgiia (Mosk) (2010) 0.75
[The influence of immunotropic drugs on reparative processes in the lungs experimental chemotherapy drug resistant tuberculosis]. Eksp Klin Farmakol (2014) 0.75
[Cycloferon, as an agent in the therapy and urgent prophylaxis of influenza and acute respiratory tract viral infection (multicentre randomized controlled comparative study)]. Antibiot Khimioter (2009) 0.75
[Characteristics of intrathoracic tuberculosis in children]. Probl Tuberk (1982) 0.75
[Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia]. Vopr Onkol (1999) 0.75
[Comparative study of hepatoprotective action of remaxol, reamberin and ademethionine in liver injury induced by antituberculosis drugs (experimental study)]. Antibiot Khimioter (2011) 0.75
[Therapeutic efficiency of cytoflavine solution for infusion in emergency conditions]. Klin Med (Mosk) (2010) 0.75
[Efficiency of using cycloferon as part of combined therapy for chronic hepatitis C (a review of multicenter clinical trials)]. Ter Arkh (2010) 0.75
[Cephalosporins as possible methods of etiotropic therapy of tuberculosis]. Probl Tuberk (1993) 0.75
[Modified therapy of herpetic infection]. Klin Med (Mosk) (2011) 0.75
[Improvement of natural resistance in children for prophylaxis of influenza and acute respiratory tract viral infections (results of multicenter randomized trials)]. Antibiot Khimioter (2009) 0.75
[Exudative pleurisy in children]. Probl Tuberk (1979) 0.75
[Combined cycloferon treatment of tuberculosis in patients infected with HIV]. Eksp Klin Farmakol (2010) 0.75
[Prevention of tuberculosis: current approaches to development of vaccines]. Vestn Ross Akad Med Nauk (2012) 0.75
[Neuroprotective effect of cytoflavin in closed craniocerebral trauma]. Eksp Klin Farmakol (2004) 0.75
[Free-radical oxidation and antioxidant protection by experimental cholestasis]. Khirurgiia (Mosk) (2011) 0.75
[The use of cycloferon in the therapy of experimental herpetic keratitis]. Antibiot Khimioter (2000) 0.75
[Enhancement of the activity of antitubercular agents with other antimicrobial agents]. Probl Tuberk (1994) 0.75
[History of St. Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia]. Probl Tuberk Bolezn Legk (2003) 0.75
[Preclinical study of Reamberin and Remaxol safety]. Eksp Klin Farmakol (2010) 0.75
Inhibitory effect of synthetic interferon inductor Cycloferone on 1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Cancer Lett (2000) 0.75
[Cycloferon--a new domestic preparation for the prophylaxis of influenza and other acute respiratory viral infections]. Zh Mikrobiol Epidemiol Immunobiol (2005) 0.75
[Destructive tuberculosis of the lung in adolescents]. Probl Tuberk (1977) 0.75
[Study of detoxifying efficacy of remaxol in experimental model of cisplatin-induced toxicosis]. Eksp Klin Farmakol (2011) 0.75
[Immunomodulators in combined therapy of patients with chronic hepatitis]. Antibiot Khimioter (2011) 0.75
[The effect of cycloferon administration on the growth of transplantable tumors in rats and mice]. Vopr Onkol (1998) 0.75
[The complex energy correction of chronic brain ischemia]. Zh Nevrol Psikhiatr Im S S Korsakova (2011) 0.75
[Extrathoracic and disseminated sarcoidosis in children, teenagers, and adolescents]. Probl Tuberk (1982) 0.75
[Surgical treatment of bilateral forms of pulmonary tuberculosis]. Probl Tuberk (2002) 0.75
[The effect of runihol and exogenous S-adenosyl-L-methionine on the morphological pattern of the liver upon hepatotoxic exposure to reserve-series antituberculous drugs]. Arkh Patol (2013) 0.75
[Differential diagnosis of disseminated pulmonary tuberculosis in children]. Probl Tuberk (1977) 0.75
[Reparative osteogenesis after incorporation of roncoleukin into therapy for experimental tuberculous gonitis]. Arkh Patol (2014) 0.75
[Rational pharmacotherapy and correction of immunity disorders in children with chronic hepatitis (clinical review)]. Antibiot Khimioter (2010) 0.75
[Reamberin for pathogenetic therapy of acute and chronic viral diseases of the liver]. Klin Med (Mosk) (2010) 0.75
[The epidemiologic significance of the resistance of tuberculosis mycobacteria to isonicotinic acid hydrazide]. Probl Tuberk (1971) 0.75
[Cycloferon in treating duodenal ulcers in rats]. Eksp Klin Farmakol (2002) 0.75
[Up-to-date approach to treatment of inflammatory infections in the maxillofacial region]. Antibiot Khimioter (2009) 0.75
[Efficacy of cytoflavin in therapy of encephalophathy in patients with neuroinfection]. Antibiot Khimioter (2010) 0.75
[Correction of free radical processes by a succinic acid drug (reamberine) in intensive care of patients with acute neurotropic poisoning]. Anesteziol Reanimatol (2001) 0.75
[Correction of adverse reactions in antimicrobial therapy of respiratory tract tuberculosis]. Antibiot Khimioter (2008) 0.75
[Cycloferon in the treatment of infectious diseases]. Antibiot Khimioter (2008) 0.75
[Possibilities for the correction of immune disorders during tuberculosis infection]. Klin Med (Mosk) (2010) 0.75
[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2008) 0.75
[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)]. Antibiot Khimioter (2010) 0.75
[Effect of antiviral drugs with various mechanisms of action on morphogenesis of infection caused by extremely pathogenic influenza virus strains in animals]. Eksp Klin Farmakol (2011) 0.75
Experimental study of biological activity of angiogen in experimental cardiovascular and hemostasis pathology. Bull Exp Biol Med (2002) 0.75
[Antiamnesic effect of cytoflavin and neuronol in rats with ischemic impairment of cerebral circulation]. Eksp Klin Farmakol (2004) 0.75
[Training of high-skilled researchers at the Saint-Petersburg Research Institute of Phtisiopulmonology in 1994-1998]. Probl Tuberk (1999) 0.75
[Chemotherapy of chronic viral hepatitis B: randomized multicenter investigation results]. Eksp Klin Farmakol (2010) 0.75
[Remaxol restores the liver antioxidant protection system in experimental cyclophosphan-induced injury]. Eksp Klin Farmakol (2011) 0.75
[Elastic materials in surgery for inflammatory diseases of the vertebral column]. Probl Tuberk Bolezn Legk (2006) 0.75
[A device for supporting the legs during lymphography]. Vestn Khir Im I I Grek (1989) 0.75
[The use of cycloferon in experimental radiotherapy of tumors]. Vopr Onkol (1999) 0.75
[Cycloferon efficacy of therapy of chronic hepatitis B (results of randomized multicentre study)]. Antibiot Khimioter (2010) 0.75
[An experimental study of the efficiency of cycloferon in the complex chemotherapy of generalized drug-resistant tuberculosis]. Eksp Klin Farmakol (2012) 0.75
[Immunotropic activity of antimicrobial agents used in tuberculosis]. Probl Tuberk (1996) 0.75
[Cycloferon in emergency prophylaxis of respiratory viral infections and influenza]. Klin Med (Mosk) (2011) 0.75
[Effectiveness of cycloferon in treating virus-associated inflammatory gynecologic diseases]. Vopr Virusol (1999) 0.75
[Use of cytoflavin for correction of complications of myocardial infarction]. Eksp Klin Farmakol (2002) 0.75
[Activities of the Tuberculosis Chair of the Central Institute of Graduate Training of Physicians 1931-1980]. Probl Tuberk (1980) 0.75
[Cycloferon efficacy in viral and bacterial diseases of children (clinical review)]. Antibiot Khimioter (2010) 0.75
[Effect of cycloferon on dissemination of Lewis lung carcinoma in mice and rhabdomyosarcoma ra-23 in rats]. Vopr Onkol (1999) 0.75